Vanda Pharmaceuticals Inc. (VNDA) has received a notice of approval from the U.S. Patent and Trademark Office for a patent application related to PONVORY (ponesimod). This application covers methodologies designed to mitigate clinical management events prior to or during multiple sclerosis treatment, and processes for resuming treatment after skipped doses.
Once issued, the patent is expected to remain valid until October 10, 2042.
Vanda has stated its intention to list this patent in the Approved Drug Products with Therapeutic Equivalence Evaluations publication, more commonly referred to as the Orange Book, a U.S. Food and Drug Administration document.
Ownership rights to PONVORY for the U.S. and Canada were acquired by Vanda from Actelion Pharmaceuticals Ltd, a subsidiary of Johnson & Johnson.
The U.S. Food and Drug Administration and Health Canada have both given approval for PONVORY to be used for adult treatment of various types of recurring multiple sclerosis. These include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
